ACXP vs. CLSE
ACXP (Acurx Pharmaceuticals, Inc.) is a stock, while CLSE (Convergence Long/Short Equity ETF) is Long-Short fund actively managed by Convergence Investment Partners. Over the past 3 years, ACXP returned -69.14%/yr vs 31.29%/yr for CLSE. At a 0.08 correlation, their price movements are largely independent.
Performance
ACXP vs. CLSE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ACXP achieves a -39.36% return, which is significantly lower than CLSE's 24.77% return.
ACXP
- 1D
- -1.95%
- 1M
- -23.35%
- YTD
- -39.36%
- 6M
- -56.23%
- 1Y
- -86.27%
- 3Y*
- -69.14%
- 5Y*
- —
- 10Y*
- —
CLSE
- 1D
- -1.02%
- 1M
- 3.46%
- YTD
- 24.77%
- 6M
- 23.28%
- 1Y
- 48.27%
- 3Y*
- 31.29%
- 5Y*
- —
- 10Y*
- —
ACXP vs. CLSE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
ACXP Acurx Pharmaceuticals, Inc. | -39.36% | -84.71% | -78.75% | -3.77% | -2.93% |
CLSE Convergence Long/Short Equity ETF | 24.77% | 20.44% | 35.54% | 17.54% | -4.38% |
Correlation
The correlation between ACXP and CLSE is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Feb 22, 2022 | 0.08 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ACXP vs. CLSE — Risk / Return Rank
ACXP
CLSE
ACXP vs. CLSE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and Convergence Long/Short Equity ETF (CLSE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ACXP | CLSE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -4.02 | ||
| Sortino ratioReturn per unit of downside risk | -5.63 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.62 | -0.71 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 10.00 | -10.97 |
| Martin ratioReturn relative to average drawdown | -1.25 | 36.36 | -37.61 |
Loading charts...
Drawdowns
ACXP vs. CLSE - Drawdown Comparison
The maximum ACXP drawdown since its inception was -99.14%, which is greater than CLSE's maximum drawdown of -16.45%. Use the drawdown chart below to compare losses from any high point for ACXP and CLSE.
Loading charts...
Drawdown Indicators
| ACXP | CLSE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.14% | -16.45% | -82.69% |
Max Drawdown (1Y)Largest decline over 1 year | -89.26% | -4.85% | -84.41% |
Max Drawdown (3Y)Largest decline over 3 years | -98.83% | -16.45% | -82.38% |
Current DrawdownCurrent decline from peak | -99.04% | -1.02% | -98.02% |
Average DrawdownAverage peak-to-trough decline | -69.51% | -3.56% | -65.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 69.15% | 1.33% | +67.82% |
Volatility
ACXP vs. CLSE - Volatility Comparison
Acurx Pharmaceuticals, Inc. (ACXP) has a higher volatility of 12.17% compared to Convergence Long/Short Equity ETF (CLSE) at 4.22%. This indicates that ACXP's price experiences larger fluctuations and is considered to be riskier than CLSE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ACXP | CLSE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.17% | 4.22% | +7.95% |
Volatility (6M)Calculated over the trailing 6-month period | 119.74% | 10.55% | +109.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 188.57% | 13.65% | +174.92% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 140.92% | 13.92% | +127.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 140.92% | 13.92% | +127.00% |
Dividends
ACXP vs. CLSE - Dividend Comparison
ACXP has not paid dividends to shareholders, while CLSE's dividend yield for the trailing twelve months is around 0.76%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
ACXP Acurx Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
CLSE Convergence Long/Short Equity ETF | 0.76% | 0.95% | 0.93% | 1.21% | 0.85% |
Frequently Asked Questions
ACXP and CLSE have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ACXP has higher volatility (12.17%) compared to CLSE (4.22%). In terms of maximum drawdown, ACXP dropped -99.14% vs CLSE's -16.45%.
CLSE currently has the higher Sharpe Ratio (3.56 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ACXP and CLSE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer